AVITA Medical, Inc.
RCEL Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$15.18
KIRA · Stoqly’s AI analyst, in plain words
- AVITA Medical, Inc. had $71.6M of revenue in fiscal 2025, up 11.5% on the year before. Over five years, revenue changed +19.6% a year on average.
- Its operating margin was −59.4%, up 28.7 pts: of every 100 in sales, about −59 is left after running the business.
- AVITA Medical, Inc. lost $48.6M in fiscal 2025.
- Free cash flow was −$32.2M in fiscal 2025, −45.0% of revenue.
- AVITA Medical, Inc. owes $24.8M more than it holds in cash.
Market cap
$467M
P/E
—
Revenue
$71.6M
Net income
−$48.6M
Free cash flow
−$32.2M
Operating margin
−59.4%
AVITA Medical, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+11.5%
Yes. Sales grew 11.5% last year.
Does it make a profit?
−67.8%
No. It lost money last year.
Does profit turn into cash?
−45.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AVITA Medical, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 12, 2026
- Legal name
- AVITA Medical, Inc.
- CIK
- 0001762303
AVITA Medical, Inc. · RCEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY20 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $29.2M | — | $50.1M | $64.3M | $71.6M |
| Revenue growth | 104.9% | — | — | 28.1% | 11.5% |
| Gross margin | 79.6% | — | 84.5% | 85.8% | 82.1% |
| Operating margin | −90.8% | — | −85.1% | −88.1% | −59.4% |
| Net income | −$26.6M | — | −$35.4M | −$61.8M | −$48.6M |
| Net margin | −90.9% | — | −70.6% | −96.3% | −67.8% |
| Diluted EPS | $1.17 | — | −$1.40 | −$2.39 | −$1.74 |
| Cash | |||||
| Cash from operations | −$25.9M | — | −$38.0M | −$48.9M | −$31.2M |
| Capital expenditure | $0.9M | — | $1.4M | $9.2M | $1.0M |
| Free cash flow | −$26.8M | — | −$39.4M | −$58.1M | −$32.2M |
| FCF margin | −91.7% | — | −78.6% | −90.4% | −45.0% |
| Share count change | 11.7% | — | — | 2.2% | 7.6% |
| Debt and strength | |||||
| Cash and short-term investments | $111M | $79.3M | $89.1M | $35.9M | $18.2M |
| Debt incl. finance leases | — | — | $39.8M | $42.2M | $43.0M |
| Shareholders' equity | $116M | $84.7M | $49.1M | $4.5M | −$16.7M |
| Current ratio | 16.4x | 8.2x | 7.9x | 2.8x | 0.6x |
| Interest coverage | −1,206.4x | — | −37.3x | −10.6x | −8.5x |
| Returns and quality | |||||
| Return on capital | — | — | — | −411.7% | −412.3% |
| Return on equity | −28.3% | — | −52.9% | −231.0% | — |
| Return on tangible equity | −23.1% | — | −72.8% | — | — |
| Piotroski F-score | 5 | — | — | 3 | 2 |
| Altman Z'' | 11.1 | — | −5.1 | −16.4 | −32.1 |
Insiders bought, 12 months
$0.2M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AVITA Medical, Inc. · RCEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.18 a share, the company is worth $467M.
Source: SEC EDGAR XBRL filings (CIK 0001762303). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.